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ggressive Therapy Is
ot Always the Best Therapy*
lbert V. G. Bruschke, MD, PHD, FACC,
. Wouter Jukema, MD, PHD, FACC
eiden, the Netherlands
he 4S (Scandinavian Simvastatin Survival Study), which
as published in 1994, was the first large clinical study to
how a significant reduction of mortality and major coronary
vents in patients with coronary artery disease who were
reated with 20 mg simvastatin (1). The reduction of relative
isk seemed to be independent of baseline lipid levels;
owever, patients with a baseline serum cholesterol level of
213 mg/dl were not included in the study (2). At about
he same time, the angiographic trial REGRESS (Regres-
ion Growth Evaluation Statin Study), which included
atients with a baseline serum cholesterol level between 155
nd 310 mg/dl, showed a highly significant beneficial effect
f 40 mg pravastatin on progression of coronary atheroscle-
osis, and the magnitude of this effect seemed to be the same
n all quartiles of baseline total cholesterol and low-density
ipoprotein cholesterol (LDL-C) (to convert from mg/dl to
mol/l, multiply by 0.026) (3).
See page 914
These and similar studies clearly showed that in the new
ra of statin treatment, old concepts about thresholds of
erum lipid levels below which patients with coronary artery
isease did not qualify for lipid-lowering therapy were no
onger tenable. Now the main issues for discussion and
esearch have become: 1) Does a threshold for baseline lipid
evels exist below which lipid-lowering therapy is not
eneficial, and if so, what are the threshold values? 2) If a
atient qualifies for lipid-lowering therapy, then how inten-
ive should statin therapy be to reach a threshold at which
he benefits still outweigh potential adverse effects? Neither
uestion has thus far been resolved, but recently more data
re becoming available, such as the analysis by Giraldez
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology, Leiden University Medical Center, Leiden,f
he Netherlands. Dr. Jukema has received research grants from Bristol-Myers Squibb,
fizer, and AstraZeneca.t al. (4) presented in this issue of the Journal, which may
ventually lead to definitive answers.
The CARE (Cholesterol And Recurrent Events) trial
as the first study to indicate a therapeutic target LDL-C
evel (5). The trial showed that treatment with pravastatin
educed the coronary event rate significantly in patients who
ad experienced a myocardial infarction and who had
verage serum lipid levels. It also showed that the event rate
eclined as LDL-C levels achieved during follow-up de-
reased, but no further decline was seen in patients having
DL-C levels below 125 mg/dl, suggesting a target LDL-C
etween about 125 mg/dl and 100 mg/dl. A similar trial,
amed the LIPID (Long-term Intervention with Pravasta-
in in Ischemic Disease) trial, included 9,014 patients with
broad range of initial cholesterol levels. No significant
elation between risk reduction and baseline lipid levels was
ound, that is, risk reduction was essentially the same in all
ubgroups of lipids, albeit that risk reduction in the pre-
efined subgroup with the lowest LDL-C (135 mg/dl)
as somewhat lower than in the other LDL-C subgroups
16% vs. 26% and 30%, respectively) (6). Several large
rimary and secondary prevention trials have followed that
ll yielded basically the same results.
In 2005 a meta-analysis of data from 90,056 participants
n 14 randomized trials of statins was published that
onfirmed the findings of most of the separate trials, namely
hat statin treatment significantly reduces the 5-year inci-
ence of all major coronary events (7). The meta-analysis
lso showed that the relative risk reduction was related to
he absolute reduction in LDL-C but largely unrelated to
he initial lipid profile or other presenting characteristics.
This raises the question: should treatment with statins
arget at achieving maximal reduction of serum lipids? In
ther words, does the hypothesis “the lower the better” hold
rue? Surprisingly, in spite of the enormous number of
articipants, in none of the trials included in the meta-
nalysis was this question addressed directly because in each
rial placebo was compared with a standard, by current
riteria mostly moderate, dose of statin. It was not until 10
ears after 4S was published that the first reports comparing
ifferent doses of statins were published.
The TNT (Treating to New Targets) trial compared the
ffects of 10 and 80 mg atorvastatin in 10,001 patients with
linically evident coronary heart disease and LDL levels
130 mg/dl over a median follow-up period of 4.9 years
8). The incidence of major cardiovascular events was 10.9%
n the patients receiving 10 mg atorvastatin and 8.7% in the
0-mg group. The relative reduction in risk was higher in
atients with baseline LDL 125 mg/dl as compared with
atients with lower LDL-C levels (34% vs. 7% reduction of
azard ratio). The highest risk reduction occurred in pa-
ients with chronic kidney disease (n  3,107), and if these
atients were excluded, the relative risk reduction decreased
rom 22% to 15% overall (9).
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Editorial Comment September 9, 2008:921–3The IDEAL (Incremental Decrease in End Points through
ggressive Lipid Lowering) study compared the effects of
torvastatin 80 mg and simvastatin 20 mg and found no
ignificant difference between the 2 treatment groups for the
rimary outcome, but there were fewer occurrences of second-
ry end points in the atorvastatin 80-mg group (10). A
elationship with baseline lipid levels could not be assessed
ecause the majority of patients received statin treatment
efore enrollment.
The PROVE IT–TIMI 22 (Pravastatin or Atorvastatin
valuation and Infection Therapy–Thrombolysis In Myo-
ardial Infarction 22) trial compared the effects of 40 mg
ravastatin and 80 mg atorvastatin in patients who had
ecently been hospitalized for an acute coronary syndrome
nd had a serum total cholesterol level 240 mg/dl (11).
fter an average follow-up period of 24 months, there was
16% reduction in the hazard ratio in favor of atorvastatin
0 mg. The current study by Giraldez et al. (4) is an
mportant substudy of the PROVE IT–TIMI 22 trial in
hich they investigate the significance of baseline LDL-C
n predicting which patients will benefit most from intensive
reatment compared with moderate treatment. For this
ubstudy, only statin-naïve patients (n  2,986, which is
2% of the total cohort) were selected, which allows a
eliable interpretation of LDL-C baseline levels and signif-
cantly contributes to the value of the findings. The study
hows convincingly and in more detail than previous studies
hat the additional benefit of intensive treatment with
tatins compared with moderate treatment declines with
ecreasing baseline LDL-C levels and that a benefit is no
onger demonstrable in patients with LDL-C levels 66
g/dl. This finding has important clinical consequences in
hat it strongly suggests that intensive, also termed aggres-
ive, treatment with statins may have more deleterious than
eneficial effects in patients with low baseline LDL-C
70 mg/dl). The question now is: does the current
nalysis conclusively answer the issue of if and when
ggressive treatment is warranted? Unfortunately, in spite of
he strong evidence presented by the investigators, the
nswer must still be: no. Similar to any other study, this
nalysis is subject to limitations, most of which are ad-
ressed by the investigators themselves in their article.
urthermore, the follow-up period was relatively short, and
t is not certain that the results obtained in patients with
cute coronary syndrome may be extrapolated without
estrictions to all patients with coronary artery disease. The
act that 2 different statins with slightly different effects on
he lipid profile and perhaps different pleiotropic properties
ere used makes it difficult to ascertain whether all differ-
nces between the 2 regimens may solely be explained by the
ntensity of lipid lowering. In view of the important clinical
s well as economical consequences, this study should be
ollowed by studies that specifically address remaining
uestions. However, it is unrealistic to expect that the
reatment of individual patients can be fully optimized by
sing the same target lipid levels for all patients. There are
1arked variations concerning the vascular susceptibility for
ipids, as is shown by the fact that individuals with low lipid
evels and no other obvious risk factors may be affected by
oronary atherosclerosis and vice versa. Progress has already
een made in identifying genetic factors that are helpful in
redicting the clinical effect of treatment with statins
12,13), but much research is still needed to establish a
ound basis for individualized treatment. In the meantime,
he observations of Giraldez et al. (4), which indicate that
here probably is an actual target LDL-C to reach by
ipid-lowering therapies of different intensities, is of great
ractical importance and merit serious consideration in the
reatment of patients. We also concur with their conclusion
hat the analyses corroborate current guideline recommen-
ations. Aggressive lipid-lowering therapy may be war-
anted in certain cases, but moderation is likely indicated if
aseline lipid levels so suggest.
eprint requests and correspondence: Dr. Albert V. G. Bruschke,
taff Center Department of Cardiology, LUMC-C5-P, Postbus
600, 2300RC Leiden, the Netherlands. E-mail: abruschke@
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